NCT02975297View on ClinicalTrials.gov

Exenatide Once Weekly for Smoking Cessation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions
Smoking Cessation
Interventions
DRUG

Exenatide

Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.

DRUG

NRT

Nicotine Patch (21mg) / 24 hours.

BEHAVIORAL

Counseling

Brief individual behavioral smoking cessation counseling.

DRUG

Placebo

Normal saline.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT02975297 - Exenatide Once Weekly for Smoking Cessation | Biotech Hunter | Biotech Hunter